Baylor University

Oxigene, Inc.

Joseph Anthony Prezioso

Kevin G Pinney

David J Chaplin

Klaus Edvardsen

Robert Ronald Kane

Charles Manly Garner, Iii

Zhi Chen

James Michael Dorsey

Vani P Mocharla

Mallinath Hadimani

Charles M Garner

Mark Wood

Raymond Kessler

Usha Ghatak, Legal Representative

Usha R Ghatak, Legal Representative

Jimmy Kessler

Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Functionalized stilbene derivatives as improved vascular targeting agents

Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.

Compositions and methods with enhanced therapeutic activity

A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.

Tubulin binding ligands and corresponding prodrug constructs

Tubulin binding agents and corresponding prodrug constructs

Growing community of inventors

Boston, MA, United States of America

Joseph Anthony Prezioso